Surgical site infection prophylaxis strategies for cardiothoracic surgery: A decision-analytic model

References

• Edwards JR, Peterson KD, Andrus ML, Dudeck MA, Pollock DA, Horan TC. National Healthcare Safety Network (NHSN) Report, data summary for 2006 through 2007, issued November 2008. Am J Infect Control 2008;36:609–26.
   PubMedGoogle Scholar
• Owens CD, Stoessel K. Surgical site infections: epidemiology, microbiology and prevention. J Hosp Infect2008; 70(Suppl 2):3–10.
   PubMedGoogle Scholar
• Kaye KS, Engemann JJ, Mozaffari E, Carmeli Y. Reference group choice and antibiotic resistance outcomes. Emerg Infect Dis 2004;10:1125–8.
   PubMedGoogle Scholar
• Kaye KS, Anderson DJ, Choi Y, Link K, Thacker P, Sexton DJ. The deadly toll of invasive methicillin-resistant Staphylococcus aureus infection in community hospitals. Clin Infect Dis 2008;46:1568–77.
   PubMedGoogle Scholar
• Garey KW, Dao T, Chen H, Amrutkar P, Kumar N, Reiter M, Gentry LO. Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections. J Antimicrob Chemother 2006;58:645–50.
   PubMedGoogle Scholar
• Weber WP, Marti WR, Zwahlen M, Misteli H, Rosenthal R, Reck S, . The timing of surgical antimicrobial prophylaxis. Ann Surg 2008;247:918–26.
   PubMed Web of Science ®Google Scholar
• Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004;38:1706–15.
   PubMed Web of Science ®Google Scholar
• Griffith RS. Introduction to vancomycin. Rev Infect Dis 1981;3(Suppl):S200–4.
   Google Scholar
• Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006;42(Suppl 1):S35–9.
   Google Scholar
• Kachroo S, Dao T, Zabaneh F, Reiter M, Larocco MT, Gentry LO, . Tolerance of vancomycin for surgical prophylaxis in patients undergoing cardiac surgery and incidence of vancomycin-resistant Enterococcus colonization. Ann Pharmacother 2006;40:381–5.
   PubMedGoogle Scholar
• Ford CW, Zurenko GE, Barbachyn MR. The discovery of linezolid, the first oxazolidinone antibacterial agent. Curr Drug Targets Infect Disord 2001;1:181–99.
   PubMedGoogle Scholar
• Stalker DJ, Jungbluth GL, Hopkins NK, Batts DH. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 2003;51:1239–46.
   PubMed Web of Science ®Google Scholar
• Conte JE Jr, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002;46:1475–80.
   PubMed Web of Science ®Google Scholar
• Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001; 45:1843–6.
   PubMed Web of Science ®Google Scholar
• Lovering AM, Zhang J, Bannister GC, Lankester BJ, Brown JH, Narendra G, . Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002; 50:73–7.
   PubMed Web of Science ®Google Scholar
• Metallidis S, Nikolaidis J, Lazaraki G, Koumentaki E, Gogou V, Topsis D, Theodoridis G, . Penetration of linezolid into sternal bone of patients undergoing cardiopulmonary bypass surgery. Int J Antimicrob Agents 2007;29:742–4. Epub 2007 Mar 19.
   PubMedGoogle Scholar
• Finkelstein R, Rabino G, Mashiah T, Bar-El Y, Adler Z, Kertzman V, . Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg 2002;123:326–32.
   PubMed Web of Science ®Google Scholar
• Bolon MK, Morlote M, Weber SG, Koplan B, Carmeli Y, Wright SB. Glycopeptides are no more effective than beta-lactam agents for prevention of surgical site infection after cardiac surgery: a meta-analysis. Clin Infect Dis 2004;38: 1357–63.
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet 2001;358:1975–82.
   PubMed Web of Science ®Google Scholar
• Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, . In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996;40:839–45.
   PubMed Web of Science ®Google Scholar
• Stevens DL, Smith LG, Bruss JB, McConnell-Martin MA, Duvall SE, Todd WM, . Randomized comparison of linezolid (PNU-100766) versus oxacillin–dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000;44:3408–13.
   PubMed Web of Science ®Google Scholar
• Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002;34:1481–90.
   PubMed Web of Science ®Google Scholar
• Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49:2260–6.
   PubMed Web of Science ®Google Scholar
• Weigelt J, Kaafarani HM, Itani KM, Swanson RN. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 2004;188:760–6.
   PubMed Web of Science ®Google Scholar
• Thompson CA. CMS reveals Medicare's value-based purchasing program for hospitals. Am J Health Syst Pharm 2011;68:1062–71.
   PubMedGoogle Scholar